Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mitomycin
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mobius Therapeutics™ Granted New US Patent for Injected Ophthalmic Mitomycin-C
Details : Mitosol (Mitomycin-C) is an antibiotic, isolated from the broth of Streptomyces verticillus Yingtanensis, intended for topical application to the surgical site of glaucoma filtration surgery.
Brand Name : Mitosol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 03, 2023
Lead Product(s) : Mitomycin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?